Navigation Links
DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations
Date:12/10/2008

DNA2.0 opens DNA2.0 Ltd. in the United Kingdom and hires Michael Dyson to run European operations.

Menlo Park, CA (PRWEB) December 10, 2008 -- DNA2.0, the leading gene synthesis and protein engineering company, today announced the expansion of the company's European operations with the creation of the United Kingdom-based DNA2.0 Ltd. Michael Dyson, PhD, has been appointed as Managing Director of European Operations and will lead the new venture in the UK as well as DNA2.0's established office in Basel, Switzerland.

"The opening of our UK headquarters represents a major step in our global growth," said Jeremy Minshull, President of DNA2.0. "Even in a time of economic uncertainty, the market for gene synthesis and its many applications continues to grow rapidly in Europe. We are confident that European customers will continue to seek out our world-class customer support, fast and reliable turnaround time and the certainty that their intellectual property is completely protected."

While many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company's state-of-the-art facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0's two European locations ensure that European customers receive the same PhD-level service and support as their U.S. counterparts.

"The demand in the European marketplace for high quality synthetic genes, delivered quickly and with confidence, is tremendous," said Dr. Dyson. "We look forward to serving our European customers even more effectively through this new base of operations."

Dr. Dyson possesses more than 20 years of experience leading European customer service and sales organizations in the life sciences industry. He has particular experience growing and managing life science businesses across Europe, and prior to joining DNA2.0 he was European Managing Director for Codon Devices. He has also held chief management positions at such life science companies as Sequenom, MicroCal and PerSeptive Biosystems.

About DNA2.0:
Founded in early 2003, DNA2.0 is the leading synthetic genomics company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.

###

Read the full story at http://www.prweb.com/releases/2008/12/prweb1731564.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
4. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
5. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
6. Specialty Blades, Inc. Expands Management Team With New VP Engineering
7. CRH Medical expands Las Vegas operations
8. US Med-Equip Expands Corporate Support Center
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Data Management Solution Providers list for its expertise in eClinical Solutions. DDi has ... to serve the technology needs of global clients. DDi provides smarter technology for ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted over 250 members of South Florida’s philanthropic community at its 10th anniversary ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... Pittsburgh, PA (PRWEB) , ... February 12, 2016 ... ... serving families of the Pittsburgh metro area, celebrates the beginning of the latest ... help children develop social skills through art. Donations to this worthy cause are ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN JOSE, Calif. , Feb. 12, 2016  SI-BONE, Inc., ... Implant System ® ("iFuse"), a minimally invasive surgical (MIS) device ... announced that National Government Services, Inc. (NGS), the Medicare Administrative Contractor ... Illinois , Maine , ... Hampshire , New York , ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
Breaking Medicine Technology: